You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

NICOTINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nicotine patents expire, and what generic alternatives are available?

Nicotine is a drug marketed by Difgen Pharms, Fertin Pharma, Ivax Sub Teva Pharms, L Perrigo Co, P And L, Perrigo R And D, Aurobindo Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Pld Acquisitions, and Ppi-dac. and is included in fifty NDAs.

The generic ingredient in NICOTINE is nicotine polacrilex. There are thirty drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nicotine

A generic version of NICOTINE was approved as nicotine polacrilex by P AND L on March 15th, 1999.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NICOTINE?
  • What are the global sales for NICOTINE?
  • What is Average Wholesale Price for NICOTINE?
Summary for NICOTINE
Drug patent expirations by year for NICOTINE
Drug Prices for NICOTINE

See drug prices for NICOTINE

Drug Sales Revenue Trends for NICOTINE

See drug sales revenues for NICOTINE

Recent Clinical Trials for NICOTINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Anna Stanhewicz, PhDEarly Phase 1
Spaulding Rehabilitation HospitalEarly Phase 1
Multidisciplinary Association for Psychedelic StudiesEarly Phase 1

See all NICOTINE clinical trials

Pharmacology for NICOTINE
Medical Subject Heading (MeSH) Categories for NICOTINE
Paragraph IV (Patent) Challenges for NICOTINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NICODERM CQ Transdermal System nicotine 7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs 020165 1 2014-05-30

US Patents and Regulatory Information for NICOTINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Sa NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 213233-001 Aug 4, 2020 OTC No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Perrigo R And D NICOTINE POLACRILEX nicotine polacrilex GUM, CHEWING;BUCCAL 078968-001 Apr 23, 2008 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
P And L NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 210711-001 Oct 31, 2019 OTC No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
P And L NICOTINE POLACRILEX nicotine polacrilex TROCHE/LOZENGE;ORAL 212057-002 May 14, 2020 OTC No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

NICOTINE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Nicotine Products

Introduction

The nicotine market is undergoing significant transformations driven by changing consumer preferences, regulatory pressures, and the emergence of new products. This article delves into the current market dynamics, financial trends, and future projections of the nicotine industry.

Market Size and Growth Projections

The US nicotine market is projected to reach $91.78 billion by 2023, with a Compound Annual Growth Rate (CAGR) of 4.78%[1].

  • Globally, the modern oral nicotine products market is expected to grow at a CAGR of 26.2% from 2024 to 2030, reaching $26.42 billion by 2030[4].

Product Segmentation

The nicotine market is segmented into several key categories:

Cigarettes

  • Despite declining sales volumes since 2008, cigarettes still dominate the market in terms of value and volume. However, this segment is facing significant challenges, including declining sales and increasing regulatory pressures[2].

Vaping Products

  • Vaping products are the second-largest segment and have seen substantial growth. However, their growth is also impacted by regulatory challenges and health concerns[1].

Moist Snuff Tobacco (MST)

  • MST remains a stable segment but is not experiencing the same level of growth as newer products like nicotine pouches[1].

Cigars & Cigarillos

  • These products continue to have a niche market but are not driving the overall growth of the nicotine market[1].

Nicotine Pouches

  • Nicotine pouches are a rapidly growing segment, driven by consumer interest in alternative nicotine products. They dominated the modern oral nicotine products market with a 55.58% share in 2023[4].

Distribution Channels

Offline Distribution

  • Offline channels, such as grocery stores and retail outlets, currently lead the market due to widespread availability. However, online channels are expected to grow at a higher rate due to increased advertising and promotional efforts[1].

Online Distribution

  • Online sales are becoming increasingly important, especially for new entrants in the industry. Factors such as competitive pricing, discounts, and accessibility are driving this growth[4].

Driving Forces and Challenges

Growing Popularity of Alternative Products

  • The shift towards next-generation products like e-cigarettes, nicotine pouches, and oral nicotine products is a significant driver of market growth[1].

Regulatory Pressures

  • Increasing taxes on tobacco products and stringent regulations pose significant challenges to the industry. These regulations are aimed at reducing smoking rates and mitigating the health impacts of nicotine consumption[2].

Public Health Concerns

  • The harmful effects of nicotine and the rise in nicotine addiction among teenagers are major public health concerns. These issues are driving the growth of the nicotine addiction treatment market[3].

Emerging Trends

Social Media Influence

  • Social media is playing a crucial role in shaping consumer behavior and influencing the popularity of nicotine products, particularly among younger demographics[1].

Impact of Party Culture and Pop Culture

  • The integration of nicotine products into party and pop culture is another emerging trend, contributing to their increased visibility and appeal[1].

Penetration of Organized Retail Networks

  • The expansion of organized retail networks is improving the availability and accessibility of nicotine products, further driving market growth[1].

Tobacco-Free Oral Nicotine Products

  • Products like flavored gummies and lozenges are gaining popularity, especially among the youth, presenting both challenges and opportunities for the market[1].

Financial Performance of Tobacco Companies

Declining Cigarette Sales

  • Cigarette sales volumes have declined steadily since 2008, and despite efforts to diversify into novel products, these products still generate a small portion of the revenue. For example, novel products accounted for only 10.3% of BAT’s revenue in FY2023[2].

Real Revenue Declines

  • Many tobacco companies have experienced real revenue declines since 2016, with six out of nine companies facing reductions in real revenues. This decline is attributed to the inability to offset reduced cigarette sales through price increases and the introduction of new products[2].

Stock Performance

  • The stocks of tobacco companies have underperformed the market since 2016, contrasting with their strong performance from 2008 to 2016. This underperformance is a result of declining cigarette sales and the challenges in offsetting these declines with new products[2].

Key Market Players

The US nicotine market is dominated by a few major players:

Altria Group Inc.

  • Altria Group Inc. is a market leader in tobacco products and has been able to offset volume declines by increasing cigarette prices, although this strategy is becoming increasingly unsustainable[2].

British American Tobacco (BAT)

  • BAT has seen significant growth in its HTP (Heat-Not-Burn) and ENDS (Electronic Nicotine Delivery Systems) sales, but traditional cigarette sales remain the primary revenue source[2].

Philip Morris International Inc.

  • Philip Morris has also increased its HTP sales but faces challenges in offsetting the decline in traditional cigarette sales. The company's acquisition of Fertin Pharma highlights its move towards smoke-free nicotine offerings[2][3].

Global Expansion and Regional Insights

North America

  • North America is a leading region in the nicotine addiction treatment market and the modern oral nicotine products market, driven by advanced healthcare systems and stringent anti-smoking legislation[3][4].

Europe

  • Europe is also experiencing significant growth in the modern oral nicotine products market, driven by shifting attitudes towards smoking, increased health consciousness, and strict smoking regulations[4].

Nicotine Addiction Treatment Market

Market Growth

  • The global nicotine addiction treatment market is expected to grow from $3.23 billion in 2023 to $5.24 billion by 2028, driven by government policies, public health campaigns, and innovative treatment methodologies[3].

Teen Tobacco Addiction

  • The prevalence of tobacco addiction among teenagers is a critical factor driving the demand for nicotine addiction treatments. Flavored tobacco products are particularly appealing to the youth, leading to a heightened demand for these treatments[3].

Key Takeaways

  • The nicotine market is transitioning towards alternative products like nicotine pouches and oral nicotine products.
  • Regulatory pressures and public health concerns are significant challenges for the industry.
  • Online distribution channels are expected to grow rapidly.
  • Major players are diversifying into smoke-free nicotine offerings to mitigate declining cigarette sales.
  • The nicotine addiction treatment market is poised for substantial growth driven by public health initiatives and innovative treatments.

FAQs

What is the projected market size of the US nicotine market by 2023?

The US nicotine market is projected to reach $91.78 billion by 2023, with a CAGR of 4.78%[1].

Which segment is dominating the modern oral nicotine products market?

The nicotine pouches segment dominated the modern oral nicotine products market with a 55.58% share in 2023[4].

How are tobacco companies performing financially?

Many tobacco companies have experienced declining real revenues since 2016, and their stocks have underperformed the market. Despite growth in novel products, traditional cigarette sales remain the primary revenue source[2].

What are the key drivers of the nicotine addiction treatment market?

The market is driven by government policies, public health campaigns, and innovative treatment methodologies. The prevalence of tobacco addiction among teenagers is also a significant factor[3].

Which region is leading in the modern oral nicotine products market?

North America is the leading region in the modern oral nicotine products market, driven by advanced healthcare systems and stringent anti-smoking legislation[4].

Sources

  1. GlobeNewswire: Shifts in US Nicotine Consumption: A Look at Products, Distribution, and Market Dynamics.
  2. BMJ Tobacco Control: Evaluating the financial case for investing in, or divesting from, tobacco companies.
  3. GlobeNewswire: Nicotine Addiction Treatment Market Report 2024.
  4. Grand View Research: Modern Oral Nicotine Products Market Size Report, 2030.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.